MAPT and Alzheimer disease: Cerebrospinal fluid (CSF) biomarkers, such as the amyloid-beta protein 42 (Aβ42), the total tau (t-tau), and phosphorylated tau (p-tau), have been included in the current criteria for AD diagnosis [7, 8].